Last updated on September 2017

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer


Brief description of study

The investigators propose to influence estrogen receptor (ER) signaling by combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast cancer.

Clinical Study Identifier: NCT02907918

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Foluso O Ademuyiwa, M.D., MPH

St. Elizabeth Physicians
Edgewood, KY United States
  Connect »

Foluso O Ademuyiwa, M.D., MPH

Washington University School of Medicine
Saint Louis, MO United States
  Connect »

Gary Unzeitig, M.D.

Laredo Breast Care
Laredo, TX United States
  Connect »